Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer
- 1 March 1990
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 36 (3) , 369-370
- https://doi.org/10.1016/0090-8258(90)90144-a
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Phase II trial of VP-16-213 in advanced ovarian carcinomaGynecologic Oncology, 1985
- Etoposide—chemistry, preclinical and clinical pharmacologyCancer Treatment Reviews, 1982
- Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agentsGynecologic Oncology, 1978
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid TumoursBMJ, 1973